Bruce Linton, Founder and Former CEO of Cannabis Industry Titan Canopy Growth and Early Investor and Advisor to Top Psychedelics Firm MindMed is Expected to Join the New Combined Company as the Non-Executive Chairman of The HighBrid Lab’s Board of Directors
As cannabis has become more and more mainstream, there is a growing appetite for legalizing other drugs and bringing them to market for medical use. One group of drugs gaining traction in the U.S. and Canada are psychedelics. Every few months it seems, there is a new study showing that drugs like psilocybin (magic mushrooms), MDMA (ecstasy) and ketamine have real and potentially groundbreaking medical benefits in treating ailments like addiction, PTSD and a host of other mental disorders.
Lawmakers are beginning to come around to the idea of certain psychedelics taking the route of legalizing medical cannabis: start at the local/state level and build support to push the federal government to follow along. The biggest domino to fall thus far was the state of Oregon decriminalizing psilocybin and legalizing it for medical use. Kevin Matthews, one of the leading figures behind Denver decriminalizing magic mushrooms, thinks the future is bright for psychedelics:
As the opportunity for bringing psychedelics to market expands, so too does the interest of investors and entrepreneurs, especially among veterans of the legal cannabis industry. Bruce Linton, the founder of Canadian cannabis giant Canopy Growth (TSX: WEED) (NASDAQ: CGC) (FRA: 11L1), has been one of the main drivers of the nascent psychedelics industry. After departing Canopy, Linton went on to join the board of directors at MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ), a contender for the top psychedelic company in the world.
Most recently, Linton joined the Board of Directors at the newly formed The HighBrid Lab. The HighBrid Lab is the name of the company formed as a result of the merger between Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) a global cannabis company based out of Australia, and Red Light Holland (CSE: TRIP) (OTC: TRUFF) (FRA: 4YX), a supplier of legal magic mushrooms to the Netherlands.
Commenting on the game-changing merger, Linton had this to say:
“Having worked with both the Creso Pharma and Red Light Holland teams closely in the past, I am really excited by the potential this combination brings. As a merged company, The HighBrid Lab has access to four of the highest growth industry segments around, and the team, board and advisory group to make real progress within these verticals. I’m really looking forward to rolling up my sleeves and helping The HighBrid Lab get to work!”
As the name implies, The Highbrid Lab will combine Creso Pharma’s global network and deep pharmaceutical expertise with Red Light Holland’s access to one of the world’s only legal psychedelic mushroom markets. The newly formed company will seek to become the preeminent global supplier of high-quality cannabis and psychedelic products.
Source: CPH + TRIP Investor Deck
The goal at Creso Pharma (ASX: CPH) (OTC: COPHF) (FRA: 1X8) has been to market cannabis products on a global scale. Their flagship brand, cannaQIX, comprises cannabis-infused products across a variety of sectors, including therapeutics, nutraceuticals, animal health and cosmetics. The products are designed to provide users with maximum bioavailability, allowing more of the active ingredients to enter the body than other forms of delivery. The brand has perhaps the furthest reach of any cannabis brand, with products available in North America, Europe, the Middle East and Southeast Asia.
Creso Pharma also sells high-THC products, including flower, pre-rolls and hashish, to Canadian medical consumers. These products, as well non-THC products, are produced at the company’s flagship cultivation and manufacturing facility in Nova Scotia, Canada. The GMP-certified facility is capable of supplying both the Canadian market, as well as export to the EU.
Creso Pharma’s Chairman of the Board, Adam Blumenthal, commented on the synergies between the two companies:
“We are very excited to have entered into this agreement with Red Light Holland and to create a company that has the potential to become a world-leading psychedelic, CBD and recreational and medicinal cannabis company…There are a number of synergies across the businesses, which will allow the Combined Company to considerably scale up operations in the near term. Red Light’s CSE-listed vehicle will allow the Combined Company to enter the lucrative US market and we anticipate that product sales through our recreational cannabis and CBD subsidiaries will scale up significantly in the short term, underpinning early cash generation and provide additional financial flexibility across the business.”
Red Light Holland’s (CSE: TRIP) (OTC: TRUFF) (FRA: 4YX) claim to fame is its iMicrodose kit and app. iMicrodose is meant to facilitate the microdosing of psilocybin mushrooms (truffles in the local parlance), while also providing users with an online platform to discuss their microdosing experiences with other users.
The company has begun construction of its future GMP-certified manufacturing facility in the Netherlands, where it will produce the iMicrodose. While distribution is initially limited to the Netherlands, the centralized location of the country will allow for the export throughout the EU, should the rest of the continent catch up on psychedelic laws.
Commenting on the merger and how he believe Red Light will benefit, company CEO Todd Shapiro said the following:
“Red Light Holland has significant capital and expertise and is motivated for growth. The company understands the sensitive complexities of the ingredients we deal with while ensuring we continue to make a bold yet careful push to provide and increase access for immediate revenue generation and brand expansion…Merging with Creso Pharma, who also has significant cash on hand, and formulating The HighBrid Lab, with Bruce Linton as Chair of the Board, means we can expand our premium product offerings globally in the high growth CBD, THC and psychedelic sectors.”
Source: CPH + TRIP Investor Deck
The transaction will count as a reverse takeover since Creso Pharma is the larger company and The HighBrid Lab will use Red Light Holland’s ticker to trade on the CSE. Based on their closing prices at the close on June 15th, 2021, the combined company will have a Pro-forma enterprise value of C$347 million, with a Pro-forma cash balance of ~C$45 million. Creso Pharma shareholders will receive 0.395 shares of Red Light Holland for each share of Creso Pharma. Current Red Light Holland shareholders are expected to realize a ~30% premium on the deal.
The combination of Creso Pharma and Red Light Holland will result in a number of attractive synergies for the new company. Foremost is the listing on the CSE; this upgrade to the CSE provides The HighBrid Lab with a much greater pool of potential investors, which management plans to utilize to raise the funds needed for expansion. Funding is expected to be used to enter the U.S. cannabis market via a near-term acquisition, expand market share in Canada for Creso Pharma’s existing products, introduce cannabis-based Red Light Holland microdosing products and to increase psychedelic R&D at pending acquisition targets.
The HighBrid Lab executive team will consist of veterans of Creso Pharma and Red Light Holland; the seven-person Board of Directors will consist of three representatives from Creso Pharma, three representatives from Red Light Holland and Bruce Linton, who will serve as Chairman.
CEO & Director – Todd Shapiro: Currently the CEO and co-founder of Red Light Holland, Mr. Shapiro will fill the same role at The HighBrid Lab. Prior to Red Light Holland, Todd was a well-known on-air radio personality and brand ambassador. His infectious personality and ability to sell a brand should serve the company well as it seeks to enter new markets and introduce new products
Non-Executive Chairman of the Board – Bruce Linton: Perhaps the most famous of the early veterans of the Canadian cannabis industry, Bruce is a highly successful and prolific entrepreneur. He co-founded what would become Canopy Growth, the largest cannabis company in Canada. Currently, Mr. Linton holds executive and board positions at a number of companies operating in cannabis, psychedelic and tech. His ability to raise capital and get companies started on the way to explosive growth is well-documented.
Executive VP & Chief Strategy Officer – William Lay: Mr. Lay previously served as the Associate Director of Mergers & Acquisitions at Canopy Growth, where he was involved in over C$5 billion in M&A transactions. His extensive experience in business combinations will prove vital not only to the creation of The Highbrid Lab, but will serve the company well in its pursuit of acquiring an interest in the U.S. cannabis industry.
Management has laid out four verticals they will pursue as a consolidated company:
- Recreational THC: Currently, this vertical comprises the company’s Canadian operations, but management intends to enter the U.S. cannabis industry in the near term. The company will also introduce Red Light Holland-branded THC products to tap into the brand’s growing momentum and build a customer base in advance of the expected legalization of psilocybin in Canada and the U.S.
- CBD: cannaQIX has shown to be an attractive product in its existing markets and the company continues to introduce it to new markets. Notably, management has a plan to introduce the brand to the U.S., as well as utilize Red Light Holland’s distribution system to increase market penetration in the Netherlands. The company also plans to pair CBD with functional mushrooms into health and wellness products for the North American and European markets.
- Recreational psychedelics: While the company classifies their iMicrodose kits as recreational, they are not for getting high. Rather, they fall more in line with health and wellness. The Highbrid Lab will continue to build out the brand in the Netherlands and will enter additional markets in North America and Europe when laws allow. Additionally, management plans to explore the development of psychedelic retreats, where groups of like-minded individuals can gather to explore the benefits of psychedelics with the help of experts. Finally, once laws allow for the sale of truly recreational psilocybin, management will introduce a line of products under the Red Light Holland brand.
- Psychedelic research: This vertical is geared toward finding ways to use psychedelics as medicine. The lack of rigorous study and government approval is why the iMicrodose is considered a recreational product and not a medical product. The pending acquisition of psychedelics life sciences company Halucenex is central to the company’s plan to develop real, life-changing drugs out of psychedelics. Halucenex is about to begin a phase II trial exploring the use of psilocybin as a treatment for treatment-resistant depression. The HighBrid Lab is also in the process of acquiring several other psychedelic life sciences companies, including Mera Life Sciences.
The legal and moral objections to both cannabis and psychedelics are falling by the wayside at a rate that puts Earth on a course for near-global legalization in the not-too-distant future. The race for companies to get out ahead of this ever-expanding opportunity is in full force and The HighBrid Lab is leading the way. Their deep expertise in branding should lead to consumers resonating with the products, while their dedication to science should allow them to develop life-changing medications for disorders that affect hundreds of millions of people around the world.
With U.S. Pot Stocks the Hot Theme of 2021, Here’s Why Red White & Bloom Could Be One of the Cannabis Sector’s Top Performers
Creso Pharma is a paid client of The Cannabis Investor. The Cannabis Investor does not hold a position in CPH.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.